Novartis: positive CHMP opinion for Cosentyx in adolescent hidradenitis suppurativa
FROM THE WIRE · FINANCE.YAHOO.COM
Novartis (SWX:NOVN) is back in focus after a positive opinion from the European Medicines Agency's CHMP for Cosentyx in adolescent hidradenitis suppurativa, highlighting how new indications can shape sentiment around the share price. The recent CHMP opinion comes during an…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA positive EMA opinion on a new indication can support sentiment on the Novartis share price.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01The EMA's CHMP gave a positive opinion for Cosentyx in adolescent hidradenitis suppurativa.
- 02The share price is at CHF 135.76 with a 30-day return of 8.9%.
- 03The year-to-date share price return is 25.1%.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets